French Senate toughens trial requirements for new drug reimbursement
This article was originally published in SRA
The French Senate has approved the bill on reforming the drug regulatory system, together with an amendment that would raise the bar for new drug reimbursement by requiring comparative clinical trials against the gold standard therapy1,2. The Senate version would also allow class actions where patients are harmed by medicines as a result of a company's failure to meet its regulatory obligations.
You may also be interested in...
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.